The Role of Genedrive in Point of Care Method For Hepatitis C Elimination in Hemodialysis Center

Authors

  • Andri Sanityoso Sulaiman Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Nuri Dyah Indrasari Department of Clinical Pathology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Ni Made Hustrini Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Desti Rachmani Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Keywords:

Hepatitis C, chronic kidney disease, hemodialysis, genedrive, point of care

Abstract

Background: Point of care is laboratory testing conducted close to the site of the patient. Point of care assessment is essential to detect and treat the hepatitis C virus in a single visit. The potential use of Genedrive extends to remote areas and key populations Therefore, there is a need for a simple, and cost-effective examination of methods, such as Genedrive. Genedrive is a rapid and low-cost diagnostic tool for the identification and treatment selection of infectious diseases. The World Health Organization targets to eliminate hepatitis by 2030, which decreases infections by 90%, and decreases deaths by 65%. Point of care could play a significant role in contributing to the elimination of hepatitis C. Chronic kidney disease (CKD) patients on hemodialysis are among the population at risk of hepatitis C due to nosocomial transmission. This study aimed to assess the role of Genedrive in measuring hepatitis C in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods: This study used a cross-sectional design. There were 64 CKD on Hd patients in Cipto Mangunkusumo Hospital tested by Genedrive. ROC analysis was conducted to assess significant hepatitis C among chronic kidney disease on hemodialysis. Results: The calculated detection limit of Genedrive was 3.1x103 IU/mL. Genedrive HCV assay showed 90.6% sensitivity, 96.8% specificity, 92% negative predictive value, and 97% positive predictive value to detect HCV, 10.36 positive likelihood ratio, and 0.09 negative likelihood ratio. Conclusion: Genedrive could be a simple and reliable point of care method to detect hepatitis C with chronic kidney disease on hemodialysis.

References

World Health Organization. Hepatitis C. (2021).

Salari N. The global prevalence of hepatitis C in a general population: A systematic review and meta-analysis. Travel Med Infect Dis. 2022;46:102255.

Kemenkes RI. Hasil Riskesdas 2013. (2013).

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7–11.

Kemenkes RI. Laporan Nasional_RKD2018_FINAL.pdf. Riskesdas. 2018;182–3.

Hill NR. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One. 2016;103–16. doi:10.4103/0019-5359.122734.

Widhani A, Lydia A, Gani RA, Setiati S. Serokonversi Hepatitis C pada pasien hemodialisis di RS Cipto Mangunkusumo. J Penyakit Dalam Indones. 2017;2:15.

WHO. WHO releases first-ever global guidance for country validation of viral hepatitis B and C elimination. (2021).

Parry JV, Easterbrook P, Sands AR. One or two serological assay testing strategy for diagnosis of HBV and HCV infection? The use of predictive modelling. BMC Infect Dis. 2017;17.

Firdaus R. Current molecular methods for the detection of hepatitis C virus in high risk group population: A systematic review. World J Virol. 2015;4:25.

Easterbrook PJ, Roberts T, Sands A, Peeling R. Diagnosis of viral hepatitis. Curr Opin HIV AIDS. 2017;12:302–14.

Lüllau A. Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. Eur J Gastroenterol Hepatol. 2018;30:280–3.

Citarella A. Screening, linkage to care and treatment of hepatitis c infection in primary care setting in the south of Italy. Life. 2020;10:1–9.

Llibre A. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of Hepatitis C virus. Gut. 2018;67:2017–24.

Morgan JR. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. J Viral Hepat. 2022;29:474–86.

Lamoury FMJ. Diagnostic performance and usability of the genedrive® hcv id kit in two decentralized settings in cameroon and georgia. Diagnostics. 2021; 11:1–10.

FIND. High-priority target product profile for hepatitis C diagnosis in decentralized settings: Report of a consensus meeting. 2015.

Reipold IE. Optimising diagnosis of viraemic hepatitis C infection: The development of a target product profile. BMC Infect. Dis. 2017;17.

The World Health Organisation. Guidelines on hepatitis B and C testing. Guidelines on hepatitis B and C testing. Vol. 66 (2017).

Lamoury FMJ. Evaluation of the Xpert HCV viral load fingerstick point of care assay. (2018) doi:10.1093/infdis/jiy114/4925218.

Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol. 2018;69: 916–26.

Lamoury FMJ. Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. J Infect Dis. 2018;217: 1889–96.

Mohamed Z. Time matters: Point of care screening and streamlined linkage to care dramatically improves Hepatitis C treatment uptake in prisoners in England. Int J Drug Policy. 2020;75:102608.

Hutin Y, Luhmann N, Easterbrook P. Evaluating the impact of Georgia’s Hepatitis C elimination plan: lessons learned for the global initiative. Lancet Glob Heal. 2020;8:e163–e164.

Cheng YL. We are IntechOpen, the world’s leading publisher of open access books built by scientists, for scientists TOP 1%. Intech. 2016;11:13.

Midgard H. Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs. Liver Int. 2022;42:1268–77.

Downloads

Published

2024-07-16

How to Cite

Sulaiman, A. S., Indrasari, N. D., Hustrini, N. M., & Rachmani, D. (2024). The Role of Genedrive in Point of Care Method For Hepatitis C Elimination in Hemodialysis Center. Acta Medica Indonesiana, 56(2), 185. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/2618

Issue

Vol. 56 No. 2 (2024): Acta Medica Indonesiana

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.